The Emerging Role of Arsenic Trioxide as an Immunomodulatory Agent in the Management of Multiple Myeloma

Publisher： Karger

E-ISSN： 1421-9662|116|1|1-7

ISSN： 0001-5792

Source： Acta Haematologica, Vol.116, Iss.1, 2006-07, pp. : 1-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Patient with Progressive Multiple Myeloma Treated Successfully with Arsenic Trioxide after Allogeneic Bone Marrow Transplantation

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 119-121

Karger

Access to resources Recommend Favorite

Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent

By Amadori S.   Fenaux P.   Ludwig H.   O'Dwyer M.   Sanz M.  

Current Medical Research and Opinion, Vol. 21, Iss. 3, 2005-03 ,pp. : 403-412

Informa Healthcare

Access to resources Recommend Favorite

The Future Role of Thalidomide in Multiple Myeloma

By  

Acta Haematologica, Vol. 114, Iss. 1, 2005-09 ,pp. : 18-22

Karger

Access to resources Recommend Favorite

Management of multiple myeloma in older people

By  

Reviews in Clinical Gerontology, Vol. 24, Iss. 3, 2014-08 ,pp. : 173-181

Cambridge University Press

Access to resources Recommend Favorite

Defining the Role of Renal Transplantation in the Modern Management of Multiple Myeloma and Other Plasma Cell Dyscrasias

By  

Nephron Clin Pract, Vol. 120, Iss. 4, 2012-10 ,pp. : c228-c235

Karger

Access to resources Recommend Favorite